Adipose-derived stem cells attenuate pulmonary microvascular hyperpermeability after smoke inhalation

Koji Ihara1,2,3*, Satoshi Fukuda1, Baigalmaa Enkhtaivan1, Raul Trujillo1, Dannelys Perez-Bello1, Christina Nelson1, Anita Randolph1, Suzan Alharbi1, Hira Hanif1, David Herndon4, Donald Prough1, Perenlei Enkhbaatar1

1 Department of Anesthesiology, The University of Texas Medical Branch, Galveston, Texas, United States of America, 2 Department of Plastic and Reconstructive Surgery, Kagoshima City Hospital, Kagoshima, Japan, 3 Department of Plastic and Reconstructive Surgery, Tokyo Women’s Medical School, Tokyo, Japan, 4 Department of Surgery, Shriners Hospital for Children, Galveston, Texas, United States of America

* ihara.koji@twmu.ac.jp

Abstract

Background
Pulmonary edema is a hallmark of acute respiratory distress syndrome (ARDS). Smoke inhalation causes ARDS, thus significantly increasing the mortality of burn patients. Adipose-derived stem cells (ASCs) exert potent anti-inflammatory properties. The goal of the present study was to test the safety and efficacy of ASCs, in a well-characterized clinically relevant ovine model of ARDS.

Methods
Female sheep were surgically prepared. ARDS was induced by cooled cotton smoke inhalation. Following injury, sheep were ventilated, resuscitated with lactated Ringer’s solution, and cardiopulmonary hemodynamics were monitored for 48 hours in a conscious state. Pulmonary microvascular hyper-permeability was assessed by measuring lung lymph flow, extravascular lung water content, protein content in plasma and lung lymph fluid. Sheep were randomly allocated to two groups: 1) ASCs: infused with 200 million of ASCs in 200mL of PlasmaLyteA starting 1 hours post-injury, n = 5; 2) control, treated with 200mL of PlasmaLyteA in a similar pattern, n = 5.

Results
Lung lymph flow increased 9-fold in control sheep as compared to baseline. Protein in the plasma was significantly decreased, while it was increased in the lung lymph. The treatment with ASCs significantly attenuated these changes. Treatment with ASCs almost led to the reversal of increased pulmonary vascular permeability and lung water content. Pulmonary gas exchange was significantly improved by ASCs. Infusion of the ASCs did not negatively affect pulmonary artery pressure and other hemodynamic variables.
Conclusions

ASCs infusion was well tolerated. The results suggest that intravenous ASCs modulate pulmonary microvascular hyper-permeability and prevent the onset of ARDS in our experimental model.

Introduction

Acute respiratory distress syndrome (ARDS) is a severe form of acute lung injury caused by sepsis, pneumonia, trauma, severe burn, and smoke inhalation injury [1]. Although survival from ARDS has increased in recent years with the use of intensive supportive cares, such as lung-protective ventilation and fluid-conservative management, the mortality of ARDS patients is still high [1]. Due to the lack of specific treatment, smoke inhalation injury and ARDS are a major cause of morbidity and mortality in burn patients [2]. Pathophysiological changes in the lungs after smoke inhalation injury are characterized by increased pulmonary microvascular permeability, edema formation, and airway obstruction. Chemical components of smoke stimulate the release of neuropeptides from peripheral endings of sensory neurons within the airways to induce neurogenic inflammation. Plasma extravasation and oedema then result as secondary responses. Neurogenic inflammation results in narrowing of airway lumina, which is attributable to airway mucosal hyperaemia, formation of obstructive casts in the airway, and bronchospasm. These changes result in severe impairment of respiratory gas exchange [3].

Mesenchymal stem cells (MSCs) have been shown to be beneficial in many pathological conditions, such as myocardial infarction [4], graft versus host disease [5] and spinal cord injury [6]. Believed to be multipotent cells, MSCs are capable of differentiating into multi cell types i.e., adipocytes, chondrocytes and osteocytes [7]. In addition, they can also differentiate into a variety of cell lineages that form mesenchymal tissues, such as marrow stroma, muscle, cartilage, tendon, fat, and bone [8–10]. Other studies have shown that MSCs lead to improved clearance of alveolar fluid and have anti-inflammatory effects on host tissue in preclinical models of ARDS and sepsis [11]. To date, two clinical studies (Phase 1) on the safety of MSCs use in patients with ARDS have been successfully completed [12, 13], and recently, we have reported on the beneficial effects of clinical grade human bone marrow-derived MSCs in ovine models of ARDS induced by pneumonia/sepsis [14].

In the present study, we tested the hypothesis that intravenously administered adipose-derived stem cells (ASCs) effectively ameliorate the severity of pulmonary microvascular hyper-permeability in ovine models of ARDS induced by smoke inhalation.

Material and methods

Animal care and use

This study was approved by the Institutional Animal Care and Use Committee of the University of Texas Medical Branch (1308034) and conducted in compliance with the guidelines of the National Institutes of Health and the American Physiological Society for the care and use of laboratory animals.
Surgical preparation

Ten female Merino sheep weighing 30–40 kg were surgically prepared 5–7 days before the experiment. Under aseptic conditions, the animals were chronically instrumented with multiple vascular catheters for hemodynamic monitoring as previously described [15]. In brief, under isoflurane anesthesia (IsoSol, VEDCO, St. Joseph, MO) administered via endotracheal tube, a 7F Swan-Ganz thermodilution catheter (model 131F7, Edwards Critical Care Division, Irvine, CA) was inserted into the right jugular vein through a 9.0F Intro-Flex-Percutaneous Sheath Introducer (CENTURION, Williamston, MI) and was advanced into the common pulmonary artery. The right femoral artery was cannulated, and a polyvinylchloride catheter (16-gauge, 24-in., Intracath, Becton Dickinson Vascular Access, Sandy, UT) was positioned in the descending aorta. Through a left thoracotomy at the level of the fifth intercostal space, a Silastic catheter (0.062-in. inner diameter, 0.125-in. outer diameter; Dow-Corning, Midland, MI) was positioned in the left atrium. To determine pulmonary transvascular fluid flux (lung lymph flow), a thoracotomy in the fifth and seventh intercostal space was performed, and the efferent vessel of the caudal mediastinal lymph node was cannulated with Silastic medical grade tubing (0.025-in inner diameter, Dow Corning, Midland, MI) with a modified method based on the technique of Staub et al [16]. The animal was given a 5-day recovery period. During this time, they had free access to food and water. Pre and post surgical analgesia was provided with buprenorphine (Buprenorphine SR™, SR Veterinary Technologies, Windsor, CO).

Measured variables

Before beginning studies, catheters were connected to pressure transducers (model PX4X4, Baxter Edwards Critical Care Division, Irvine, CA) with continuous flushing devices. Electronically calculated mean pressures (MAP: mean arterial pressure; CVP: central venous pressure; MPAP: mean pulmonary artery pressure; and LAP: left atrium pressure) were recorded on a monitor with graphic and digital displays (MP30, Philips, Andover, MA). Pressures were measured while sheep were standing and calm. Zero calibrations were taken at the olecranon joint on the frontal leg while the animals were standing. Core body temperature was measured with the thermistor of the Swan-Ganz catheter. 10mL of Saline solution at 1˚C served as the thermal indicator. Arterial blood gas samples were analyzed at 37˚C and carboxyhemoglobin (COHb) was measured using a conventional blood gas analyzer (RAPIDPoint 500 System, Siemens Healthcare Diagnostics, Tarrytown, NY); consequently corrected for core body temperature. The partial arterial oxygen pressure (PaO₂)/inspired oxygen fraction (FiO₂) ratio, cardiac index (CI), systemic vascular resistance index (SVRI), and oxygenation index (OI) were calculated using standard formulas. Lung lymph flow was measured with graduated test tubes and a stopwatch. Plasma and lymph protein concentrations were measured using a refractometer.

Experimental protocol

After baseline (BL) measurements and sample collections were completed in the healthy state, a tracheostomy was performed under ketamine (KetaVed, Phoenix Scientific, St. Joseph, MO) anesthesia (5mg/kg) and a cuffed tracheostomy tube (10mm diameter, Shiley, Irvine, CA) was inserted into the trachea. In addition, a Foley urinary retention catheter (C.R. Bard, Inc., Covington, GA) was placed in the urinary bladder to monitor fluid balance. Anesthesia was maintained with 2% to 5%. Isoflurane (IsoSol, VEDCO, St. Joseph, MO) in O₂. Smoke inhalation was induced using a modified bee smoker. The bee smoker was filled with 40 g of burning cotton towels and then attached to the tracheostomy tube via a modified endotracheal tube containing an indwelling thermistor from a Swan-Ganz catheter. Four sets of twelve breaths of smoke (total 48 breaths) were delivered, and the carboxyhemoglobin level was determined.
immediately after each set. The temperature of the smoke was not allowed to exceed 40°C during the smoking procedure [15, 17, 18]. Immediately after injury, anesthesia was discontinued, and the animals were allowed to awaken but were maintained on mechanical ventilation (Hamilton-G5, Hamilton Medical, Switzerland) throughout the 48-h experimental period.

After the injury, sheep were randomly allocated to one of the two groups (n = 5 each): 1) control (injured, treated with vehicle); and 2) ASCs treatment (injured, treated with 200 million of adipose-derived stem cells). The cells were administered intravenously over 30 min via central line, starting 1 h after injury.

All sheep were continuously (around the clock) monitored for 48 hours in the Translational Intensive Care Unit. The variables of hemodynamics, pulmonary function, blood gas exchange, and lung lymph flow (transvascular fluid flux) were recorded every 6 hours.

All sheep were mechanically ventilated in APVcmv mode with positive end-expiratory pressure set at 5 cmH₂O, tidal volume maintained at 12mL/kg and a respiratory rate of 20 breaths per minute. The breath rate was periodically adjusted to maintain arterial carbon dioxide tension close to baseline values. One hundred percent oxygen was delivered in the first three hours after injury to accelerate the dissociation of carbon monoxide from hemoglobin. The fraction of inspiratory oxygen was periodically adjusted to maintain the arterial oxygen tension above 95 mmHg.

All sheep received fluid resuscitation during the experiment with lactated Ringer’s solution following the Parkland formula. During experimental periods, the animals were allowed free access to food, but not to water to accurately measure fluid intake.

**ASCs isolation and culture conditions**

Subcutaneous adipose tissue was isolated from healthy sheep from the left fifth intercostal incision in preparative surgery and was washed extensively with PBS containing 2% penicillin/streptomycin. The tissue was then minced (2mm or less). Each 10 grams of minced fat tissue was placed in processing 50 ml tube with 2.5 ml of Matrase™ and up to 30 ml of lactated Ringer’s solution. Fat tissue was incubated at 37°C for 2 hours using ARC System (InGeneron, Inc). Because ovine adipose tissue has higher levels of saturated fat compared to adipose tissue from humans, longer incubation time was needed for the enzymatic digestion of the fat. Following complete digestion, solution was filtered in Steriflip™ to collect the filtrate. The filtrate was concentrated using ARC System by centrifuge at 600g for 10 minutes. Two washing steps with 60 ml of lactated Ringer’s solution were applied in order to have a pellet ofstromal vascular fraction. Finally, the pellet was re-suspended in complete media [Dulbecco’s Minimum Essential Medium with 10% FBS and 2% antibacterial/antimycotic solution (10,000IU/mL Penicillin; 10,000ug/mL Streptomycin)]. The final pellet was seeded into tissue culture flask of 175 cm², and placed in the 5% CO₂ and 37°C incubator. After incubating for 24 hours, the media was replaced to remove unattached cells and debris. Cells were cultured and frozen down in aliquots. Second passage cells were used for the experiments.

The cells were characterized as below: 1) adherence to plastic in standard culture conditions, 2) expression of specific surface antigen assessed by flow cytometer or PCR (Negative for CD45, CD31, CD14, CD11b and MHC Class II DQ/DR. Positive for CD44, CD73, CD90 and CD105), 3) differentiation potential for osteoblasts, adipocytes and chondroblasts (Fig 1).

**Necropsy**

Forty-eight hours after injury, animals were deeply anesthetized and euthanized by intravenous administration of xylazine (3.0mg/kg), ketamine (40mg/kg), and buprenorphine (0.01mg/kg) following IACUC approved protocols, and American Veterinary Medical
Association Guidelines for Euthanasia. The lower one-half of the lower lobe of the right lung was used for the determination of bloodless wet-to-dry weight ratio. The organ tissue samples were harvested, snap-frozen in liquid nitrogen and stored at -80°C for later analysis.

**Immunohistochemistry**

For the distribution study, we prepared 3 sheep in the same manner, and treated with 200 million of GFP-labeled ASCs. Sheep were euthanized 24 hours after the injury. Several organs including the lung, liver, kidney, and spleen were removed, processed and paraffin embedded. 5 μm coronal sections were stained for histopathology analysis of ASCs distribution. In preparation for immunohistochemistry (IHC), samples were deparaffinized and rehydrated in xylene, 100% and 95% alcohol. Antigen retrieval was completed in 95°C 0.01M citrate buffer pH 6 followed by a quenching process of 3% endogenous hydrogen peroxide. The sections were blocked with the endogenous avidin-biotin complex (Life Technologies; Waltham, MA) to reduce nonspecific binding. Slides were stained with primary antibody rabbit anti-GFP (1:1000; Abcam Cambridge, MA) and secondary biotinylated anti-rabbit IgG (Vector Laboratories, Burlingame, CA). Horseradish peroxidase streptavidin (Vector Laboratories, Burlingame, CA) was used for color visualization in addition to diaminobenzidine (DAB; Dako, Carpinteria, CA). Sections were counterstained with Harris hematoxylin (Protocol, Thermo-Fischer Scientific, Waltham, MA).

**Statistical analysis**

All values were expressed as means ± SEM. Statistic analysis (Prism 6 software [GraphPad Software, Inc. San Diego, CA]) was performed among the groups by two-way ANOVA, followed by post hoc Bonferroni test. COHb levels after smoke inhalation injury and wet-to-dry weight ratio between the groups were compared using non-parametric procedures (Mann-Whitney U test) after confirming non-normal distribution. A value of P < 0.05 was regarded as statistically significant.

**Results**

All animals survived the 48-hour experimental period. The arterial carboxyhemoglobin levels determined immediately after smoke exposure averaged 74.6±4.3% in the control group and 69.5±3.3% in the ASCs group. There was no significant difference between these values.
Lung lymph flow, an index of pulmonary transvascular fluid flux, was increased ~9-fold in control sheep compared to baseline (37.4 ± 14.4 at 36hr, 4.2 ± 1.1 at Baseline). This was associated with a significant total protein decrease in plasma and its increase in lung lymph. The treatment with ASCs significantly attenuated increases in lymph flow (control vs. ASCs; 31.2 ± 6.2 and 13.9 ± 3.1 at 18hr, 33.3 ± 5.6 and 18.2 ± 4.8 at 30hr, 34.1 ± 5.5 and 15.0 ± 4.3 at 36hr, p < 0.05) (Fig 2A). The plasma protein significantly decreased immediately after the injury vs. baseline and continued to drop in the control group. Treatment with ASCs prevented these changes (Fig 2B). Accumulated loss of protein with lung lymph tended to increase in both groups, but it was significantly lower after 24hrs in ASC group (Fig 2C). Moreover, the treatment with ASCs almost reversed increased pulmonary vascular permeability index [(lung lymph protein × lung lymph flow)/plasma protein] (Fig 3A) and reduced lung water content (Lung wet-to-dry weight ratio) (5.7 ± 2.6 and 7.9 ± 3.6, p = 0.0556) (Fig 3B).

PaO₂/FiO₂ ratio decreased below 300 after 24hours in control group. However, pulmonary gas exchange was significantly improved by ASCs treatment. ASCs treatment delayed the
onset of ARDS (PaO$_2$/FiO$_2$ ratio, control vs. ASCs: 262±127 and 406±101 at 24hr, 150±29 and 354±56 at 30hr, p<0.05) (Fig 4A). Oxygenation index increased markedly in the control group after 18hr and continued to increase over the 48hrs study period. The latter was significantly attenuated by ASCs (P<0.05 at 36hr and 48hr [Fig 4B]).

Peak and Pause airway pressures were increased more than 2 fold in the control group. These changes were significantly inhibited by the ASCs treatment (Fig 4C and 4D).

In treatment group, urine output was significantly higher compared to the control group at 18, 24 and 30hrs after injury (Fig 5A). Increases in accumulated net fluid balance (fluid retention) were significantly attenuated by ASCs treatment compared to control group at 42 and 48hrs after injury (Fig 5B).

**Systemic hemodynamics (Table 1)**

Mean arterial pressure increased in both groups following injury as compared to baseline values. There was no difference in comparison between the two groups. Systemic vascular resistance also similarly increased post-injury in both groups. Additionally, the pulmonary capillary wedge pressure and central venous pressure did not deviate between the two groups over the experimental period.

The pulmonary artery pressure was not affected during the 30-minute infusion of 200 million ASCs into the jugular vein. In the post-injury time, the changes in pulmonary artery pressure were comparable in both groups except it was significantly higher at 18hrs in ASCs group. Cardiac index displayed no sustained post-injury changes, and there were no differences between sheep receiving therapeutic treatment and control group.
Histopathology

Many structurally intact ASCs were detected in the lung interstitial space and seemed to migrate by changing their shape (Fig 6A). Few stained cells were found in liver vasculatures and sinus 24 hours after injury (Fig 6B). In spleen, many smaller particles were stained by anti-GFP antibody, and no structurally intact cells were detected (Fig 6C). Urinary tubules were filled by stained particles and some cells were found in glomerulus (Fig 6D), but its integrity was disrupted.

Table 1. Systemic hemodynamics.

|                | Baseline | 3     | 6     | 12    | 18    | 24    | 30    | 36    | 42    | 48    |
|----------------|----------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
|                |          |       |       |       |       |       |       |       |       |       |
| MAP, mmHg      |          |       |       |       |       |       |       |       |       |       |
| Control        | 97.8±3.6 | 108±3.8 | 105±4.7 | 99±1.8 | 94.8±2.4 | 99.2±2.9 | 95.6±2.2 | 94.4±3.9 | 97.2±1.7 | 93±4.2 |
| ASCs           | 96.6±3.1 | 114.4±3.4 | 111.0±3.0 | 103.8±3.2 | 101.8±2.6 | 96.8±4.0 | 97.6±1.5 | 99.0±4.0 | 104.4±2.1 | 101.8±3.0 |
| PAP, mmHg      |          |       |       |       |       |       |       |       |       |       |
| Control        | 20.6±0.9 | 22.0±1.6 | 24.0±1.4 | 20.2±0.7 | 21.4±1.2 | 29.0±2.5 | 29.2±2.2 | 26.4±2.3 | 26.2±1.8 | 25.8±1.8 |
| ASCs           | 22.2±2.4 | 27.4±1.7 | 28.2±1.3 | 26.4±2.8 | 30.4±2.7* | 27.4±1.5 | 27.2±1.6 | 27.8±1.9 | 28.4±1.4 | 26.2±2.3 |
| PCWP, mmHg     |          |       |       |       |       |       |       |       |       |       |
| Control        | 12.4±0.9 | 13.2±1.7 | 14.0±1.6 | 10.6±0.4 | 11.4±0.5 | 15.8±0.7 | 15.6±2.1 | 14.0±2.1 | 14.0±1.8 | 14.2±1.8 |
| ASCs           | 13.2±1.9 | 17.0±1.2 | 15.2±0.6 | 14.4±1.2 | 16.0±1.7 | 15.2±0.7 | 15.0±1.2 | 14.8±2.0 | 14.6±1.9 | 15.0±1.8 |
| CVP, mmHg      |          |       |       |       |       |       |       |       |       |       |
| Control        | 8.2±1.0  | 7.4±1.2 | 7.6±1.0 | 6.6±1.0 | 6.2±1.0 | 9.0±1.3 | 6.0±1.6 | 7.6±1.9 | 10.2±1.6 | 10.8±1.7 |
| ASCs           | 7.8±1.4  | 11.0±1.2 | 10.4±0.7 | 7.8±0.9 | 9.4±0.8 | 9.8±1.6 | 9.0±1.7 | 8.0±2.0 | 9.0±2.1 | 9.4±2.2 |
| CI, L/min×m²   |          |       |       |       |       |       |       |       |       |       |
| Control        | 6.1±0.4  | 6.2±0.5 | 5.9±0.2 | 5.6±0.3 | 5.4±0.2 | 5.1±0.6 | 5.1±0.4 | 5.2±0.3 | 5.6±0.5 | 5.9±0.2 |
| ASCs           | 6.4±0.3  | 6.7±0.4 | 6.5±0.4 | 6.3±0.2 | 6.1±0.2 | 6.2±0.5 | 5.3±0.2 | 6.0±0.4 | 6.8±0.7 | 6.0±0.7 |
| SVRI, dyne·sec·cm⁻²·m⁻² |          |       |       |       |       |       |       |       |       |       |
| Control        | 1204.2±100.7 | 1322.4±94.0 | 1325.5±66.9 | 1336.7±75.8 | 1329.1±54.3 | 1457.1±132.9 | 1444.3±117.3 | 1356.1±66.9 | 1275.3±116.6 | 1123.2±60.2 |
| ASCs           | 1120.9±44.0 | 1250.9±58.9 | 1262.7±105.5 | 1226.8±19.3 | 1208.2±59.3 | 1153.3±95.0 | 1348.2±87.5 | 1219.0±68.7 | 1177.7±142.4 | 1314.5±180.6 |

(MAP, mean arterial pressure; CVP, central venous pressure; MPAP, mean pulmonary artery pressure; and LAP, left atrium pressure)
Discussion

The main findings of the present work was as follows:

1) Intravenous administration of ASCs significantly reduced the pulmonary microvascular hyperpermeability in sheep caused by cotton smoke inhalation. This was evidenced by significantly attenuated increases in lung lymph flow, an index of pulmonary microvascular fluid flux, pulmonary microvascular hyperpermeability index and reduced lung water content. These observations were supported by the findings that ASCs significantly reduced the systemic fluid retention, increased the plasma protein, prevented protein loss in lymph, and increased the urinary output. 2) The administration of ASCs significantly improved pulmonary gas exchange, evaluated by determining PaO$_2$/FiO$_2$ ratio (arterial/inspired air oxygen partial pressures), and pulmonary oxygenation index. The treatment also significantly reduced elevated airway pressures. The data from present study suggest that ASCs treatment delayed the onset of mild ARDS and prevented the development of moderate and severe ARDS as the PaO$_2$/FiO$_2$ ratio stayed above 300 up to 30hrs and above 200 in the remaining time period. It is worth noting that the intravenous administration of ASCs was well tolerated, as there were not any negative hemodynamic changes observed, including pulmonary arterial pressure during the 30-minute infusion time.

Fig 6. Histopathology. Many structurally intact ASCs were detected in the lung interstitial space (A). Few stained cells were found in liver (B). In the spleen, many smaller particles were stained by anti-GFP antibody (C). Urinary tubules were filled by stained particles (D).
https://doi.org/10.1371/journal.pone.0185937.g006
MSCs are multipotent cells with low immunogenicity that secrete multiple anti-inflammatory cytokines capable of modulating the immune response, attenuating bacterial infection by secretion of antimicrobial peptides, and controlling oxidative stress through the transfer of functional mitochondria to the damaged host cells [11, 19–21]. It has previously been shown that MSCs from different origins ameliorated the severity of acute lung injury [22–25]. In contrast to our research, a majority of these studies were conducted with the rodent model, and treated with bone marrow-derived human mesenchymal stem cells. The sheep model has proven to be an excellent paragon for biomedical research. The anatomy and physiology of the sheep respiratory system is well understood and much more comparable to humans. Hence, the ovine model is appropriate for vaccines, asthma pathogenesis, and inhalation treatment studies.

As mentioned, adipose-derived stem cells exerted a strong effect on systemic and pulmonary microvascular hyper-permeability caused by smoke inhalation; however, the study is limited by insufficiently described mechanistic aspects underlying these salutary effects. It has been shown that beneficial effects of MSCs are mediated by many different factors including their ability to modulate innate and adaptive immune cells, by enhancing anti-inflammatory pathways, such as IL-10 and IL-1 receptor antagonist [26, 27]. Previous studies reported that MSCs alleviate severity of organ injury by their antioxidative effects [28]. MSCs attenuate neutrophil activity and protect against ventilator-induced lung injury [29]. Pati S et al. reported that bone marrow derived mesenchymal stem cells inhibit inflammation and preserve vascular endothelial integrity in the lungs after hemorrhage shock by inhibiting leucocyte adhesion molecules [30]. In our previous studies, we have demonstrated important roles of oxidative stress, neutrophil activation, adhesion molecules, and pro-inflammatory cytokines, such as IL-1 and IL-6 in smoke inhalation-induced acute lung injury in sheep model [31–38]. Thus, based on previous studies by others and our group, we speculate that ASCs may have attenuated severity of smoke inhalation-induced acute lung injury by exerting their potent anti-inflammatory (secretory function) properties.

Previous studies also reported that MSCs attenuate lung injury through lipoxin A4 (LXA4) [39, 40]. It has also been shown that potent permeability factor angiopoietin-2 (ANG2) to play a critical role in the pathophysiology of ARDS [41–43]. We have measured both LXA4 and ANG2 in the lung tissue at 48 hours (time of necropsy); however, these values were not affected by ASCs treatment, suggesting that LXA4 and ANG2 pathways are not involved in the beneficial effect of ASCs on microvascular hyper-permeability and lung tissue injury at least at 48 hours.

Another limitation of our present study is that we were not able to measure inflammatory or permeability markers in the lung tissue at different time points after the injury. It is possible that the peak time of the expression of ANG2 and LXA4 occurred much earlier; as we have reported in our previous studies that inflammatory mediators (lung IL-1β, TNF-α, IL-6) in mice lung tissue peaked around 9 hours after the injury [36]. We have also reported on the time course of cytokines in sheep sepsis study, in which IL-6 and PARP activation in lung tissue peaked at 8 hours and 12 hours after injury [37].

In the present study, we have determined the distribution of intravenously administered ASCs. We found many structurally intact ASCs in the lung parenchyma 24 hours after the injury (microscopic image). Some intact cells were also spotted in the liver sinus. However, we were not able to find intact ASCs in spleen or urine in spite of the positive signals of green fluorescent protein (GFP) by whole organ imaging or flow cytometer.

Microscopically, we found numerous small particles stained with anti-GFP antibody in spleen and renal tubules. It is worth nothing that whole organ imaging gives some idea of cell
distribution, but this method does not provide information on the cell morphology, while microscopic assay (immunohistochemistry) enables the determination of cell integrity.

Nevertheless, the above results suggest that most of the intravenously administered ASCs are deposited in the lung tissue, migrating to interstitial space. Currently, we have no evidence confirming their differentiation to lung epithelial or endothelial cells; however we do not exclude the possibility of their engraftment, thus repairing the injured cells—this hypothesis should be further investigated. It appears that there was none or minimal (liver) distribution of these cells in non-pulmonary organs at least 24 h injection (another limitation of this study is that we were not able to harvest lung tissue at different times after the ASCs infusion).

Previously, numbers of investigators reported in vivo cell distribution. Schrepfer et al. demonstrated that most of intravenously (IV) infused MSCs were trapped in the lung 5 minutes after injection, and lung passing was size dependent [44]. Fischer et al. investigated the pulmonary first-pass effect and found MSCs in carotid artery immediately post-injection, but the numbers were less than 1% of infused cells [45]. Barbash et al. showed that IV injected MSCs were redistributed in liver, kidney and bladder 4 hours after injection using whole body fluorescent imaging [46]. These studies suggest that a small amount of cells pass through the lung microvasculature. However, this notion should be confirmed by future studies with frequent sampling at various time points after the infusion.

Nevertheless, we are reporting for the first time, to our knowledge, the beneficial effects of ASCs in a clinically relevant translation ovine model of acute lung injury induced by smoke inhalation. This is of a particular importance, because there are no clinical studies demonstrating efficacy of MSCs in ARDS patients expect two phase-1 safety studies with limited numbers of patients [12, 13]. Previously, our group demonstrated beneficial effects of clinical grade human bone marrow-derived MSCs in ovine model of ALI/ARDS induced by pneumonia sepsis [14].

In conclusion, the results of our previous and present studies as well as prior studies by others, strongly suggest that ASCs could be a safe and efficient therapeutic option for the treatment of ARDS patients. These studies also indicate a need for large, multicenter and prospective clinical studies on the safety and efficacy of ASCs in ARDS patients. Future studies exploring mechanistic aspects specifically focusing on the salutary effects of ASCs on endothelial permeability are warranted.

Supporting information

S1 Data. Data of control sheep; N = 5.
(XLSX)

S2 Data. Data of treatment sheep; N = 5.
(XLSX)

Author Contributions

Conceptualization: Perenlei Enkhbaatar.

Data curation: Koji Ihara, Christina Nelson.

Formal analysis: Koji Ihara.

Investigation: Koji Ihara, Satoshi Fukuda, Baigalmaa Enkhtaivan, Raul Trujillo, Dannelys Perez-Bello, Anita Randolph, Suzan Alharbi, Hira Hanif.

Methodology: Koji Ihara, David Herndon, Donald Prough, Perenlei Enkhbaatar.
Project administration: Koji Ihara, Perenlei Enkhbaatar.
Supervision: David Herndon, Donald Prough, Perenlei Enkhbaatar.
Validation: Koji Ihara.
Visualization: Koji Ihara.
Writing – original draft: Koji Ihara.
Writing – review & editing: Perenlei Enkhbaatar.

References
1. Matthay MA, Ware LB, Zimmerman GA. The acute respiratory distress syndrome. J Clin Invest 2012; 122: 2731–2740. https://doi.org/10.1172/JCI60331 Epub 2012 Aug 1. PMID: 22850883
2. Rehberg S, Maybauer MO, Enkhbaatar P, Maybauer DM, Yamamoto Y, Traber DL. Pathophysiology, management and treatment of smoke inhalation injury. Expert Rev Respir Med 2009; 3: 283–297 https://doi.org/10.1586/ERS.09.21 PMID: 20161170
3. Enkhbaatar P, Pruitt BA Jr, Suman O, Micak R, Wolf SE, Sakurai H, et al. Pathophysiology, research challenges, and clinical management of smoke inhalation injury. Lancet 2016; 388: 1437–1446 https://doi.org/10.1016/S0140-6736(16)31458-1 PMID: 27707900
4. Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 2004; 95: 9–20 https://doi.org/10.1161/01.RES.0000135902.99383.6f PMID: 15242991
5. Le Blanc K, Rasmusson I, Sundberg B, Götterström C, Hassan M, Uzunel M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439–1441
6. McDonald JW, Liu XZ, Qu Y, Liu S, Mickey SK, Turetsky D, et al. Transplanted embryonic stem cells survive, differentiate and promote recovery in injured rat spinal cord. Nat Med 1999; 5: 1410–1412 PMID: 10581084
7. Dominici M, Bianco KL, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315–317 https://doi.org/10.1080/14653240600855905 PMID: 16923606
8. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143–147 PMID: 10102814
9. Chamberlain G, Fox J, Ashton B, Middleton J. Mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007; 25: 2739–2749 https://doi.org/10.1634/stemcells.2007-0197 PMID: 17656645
10. Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol 2004; 36: 568–584 https://doi.org/10.1016/j.biocel.2003.11.001 PMID: 15010324
11. Walter J, Ware LB, Matthay MA. Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis. Lancet Respir Med 2014; 2: 1016–1026. https://doi.org/10.1016/S2213-2600(14)70217-6 Epub 2014 Oct 28.
12. Wilson JG, Liu KD, Zhou NJ, Caballero L, McMillan M, Fang X, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med 2015; 3: 24–32. https://doi.org/10.1016/S2213-2600(14)70291-7 Epub 2014 Dec 17. PMID: 25529339
13. Liu KD, Wilson JG, Zhou HJ, Caballero L, McMillan ML, Fang X, et al. Design and implementation of the START (Stem cells for ARDS Treatment) trial, a phase ½ trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome. Ann Intensive Care 2014; 4: 22. https://doi.org/10.1186/s13613-014-0022-z eCollection 2014. PMID: 25593740
14. Aasmussen S, Ito H, Traber DL, Lee JW, Cox RA, Hawkins HK, et al. Human mesenchymal stem cells reduce the severity of acute lung injury in a sheep model of bacterial pneumonia. Thorax 2014; 69: 819–825. https://doi.org/10.1136/thoraxjnl-2013-204980 Epub 2014 Jun 2. PMID: 24891325
15. Soejima K, Schmalstieg FC, Sakurai H, Traber LD, Traber DL. Pathophysiological analysis of combined burn and smoke inhalation injuries in sheep. Am J Physiol Lung Cell Mol Physiol 2001; 280: L1233–1241 PMID: 1150893
16. Staub NC, Bland RD, Brigham KL, Demling R, Erdmann AJ 3rd, Woolverton WC. Preparation of chronic lung lymph fistulas in sheep. J Surg Res 1975; 19: 315–320 PMID: 1195727
17. Kimura R, Traber DL, Herndon DN, Linares HA, Lubbesmeyer HJ, Traber DL. Increasing duration of smoke exposure induces more severe lung injury in sheep. J Appl Physiol 1988; 64: 1107–1113 PMID: 3366733

18. Traber DL, Maybauer MO, Maybauer DM, Westphal M, Traber LD. Inhalational and acute lung injury. Shock 2005; 24: 82–87 PMID: 16374378

19. Matthay MA, Thompson BT, Read EJ, McKenna DH Jr, Liu KD, Calfee CS, et al. Therapeutic potential of mesenchymal stem cells for severe acute lung injury. Chest 2010; 138: 965–972. https://doi.org/10.1378/chest.10-0518 PMID: 20923800

20. Lee JW, Fang XH, Krasnodembksaya A, Howard JP, Matthay MA. Mesenchymal stem cells for acute lung injury: Role of paracrine soluble factors. Stem Cells 2011; 29: 913–919. https://doi.org/10.1002/stem.643 PMID: 21506195

21. Islam MN, Das SR, Emin MT, Wei M, Sun L, Westphalen K, et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med 2012; 18: 759–765. PMID: 22504485

22. Rojas M, Xu JG, Woods CR, Mora AL, Spears W, Roman J, et al. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol 2005; 33: 145–152. https://doi.org/10.1165/rcmb.2004-0330OC PMID: 15891110

23. Li J, Li D, Liu X, Tang S, Wei F. Human umbilical cord mesenchymal stem cells reduce systemic inflammation and attenuate LPS-induced acute lung injury in rats. J Inflamm (Lond) 2012; 9: 33. https://doi.org/10.1186/1476-9255-9-33 PMID: 22974286

24. Zhang S, Danchuk SD, Imhof KM, Semon JA, Scruggs BA, Bonvillain RW, et al. Comparison of the therapeutic effects of human and mouse adipose-derived stem cells in a murine model of lipopolysaccharide-induced acute lung injury. Stem Cell Res Ther 2013; 4: 13. https://doi.org/10.1186/scrt161 PMID: 23360775

25. Hao Q, Zhu YG, Mensel A, Gennai S, Lee T, Xu F, et al. Study of bone marrow and embryonic stem cell-derived human mesenchymal stem cells for treatment of Escherichia coli endotoxin-induced acute lung injury in mice. Stem Cell Transl Med 2015; 4: 832–840. https://doi.org/10.5966/scrtm.2015-0006 Epub 2015 May 21 PMID: 25999518

26. Manning E, Pham S, Li S, Vazquez-Padron RI, Mathew J, Ruiz P, et al. Interleukin-10 delivery via mesenchymal stem cells: a novel gene therapy approach to prevent lung ischemia-reperfusion injury. Hum Gene Ther 2010; 21: 713–727 https://doi.org/10.1089/hum.2009.147 PMID: 20122755

27. Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K, et al Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A 2007; 104: 11002–11007 https://doi.org/10.1073/pnas.0704421104 PMID: 17569781

28. Mohammadzadeh M, Halabian R, Gharehbaghian A, Amirizadeh N, Jahanian-Najafabadi A, Roushande AM, et al. Nrf-2 overexpression in mesenchymal stem cells reduces oxidative stress-induced apoptosis and cytotoxicity. Cell Stress Chaperones 2012; 17: 553–565

29. Lai TS, Wang ZH, Cai SX. Mesenchymal stem cell attenuates neutrophil-predominant inflammation and acute lung injury in an in vivo rat model of ventilator-induced lung injury. Chin Med J (Engl) 2015; 128: 361–367

30. Pati S, Gerber MH, Menge TD, Wataha KA, Zhao Y, et al. Bone marrow derived mesenchymal stem cells inhibit inflammation and preserve vascular endothelial integrity in the lungs after hemorrhagic shock. PLoS One 2011; 6: e25171. https://doi.org/10.1371/journal.pone.0025171 Epub 2011 Sep 28. PMID: 21980392

31. Enkhbaatar P, Traber DL. Pathophysiology of acute lung injury in combined burn and smoke inhalation injury. Clin Sci (Lond) 2004; 107: 137–143

32. Soejima K, Traber LD, Schmalstieg FC, Hawkins H, Jodoin JM, Szabo C, et al. Role of nitric oxide in vascular permeability after combined burns and smoke inhalation injury. Am J Respir Crit Care Med 2001; 163: 745–752 https://doi.org/10.1164/ajrccm.163.3.9912052 PMID: 11254334

33. Enkhbaatar P, Murakami K, Shimoda K, Mizutani A, Traber L, Phillips GB, et al. The inducible nitric oxide synthase inhibitor BBS-2 prevents acute lung injury in sheep after burn and smoke inhalation injury. Am J Respir Crit Care Med 2003; 167: 1021–1026

34. Cox RA, Burke AS, Oliveras G, Enkhbaatar P, Traber LD, Zwischenberger JB, et al. Acute bronchial obstruction in sheep: histopathology and gland cytokine expression. Exp Lung Res 2005; 31: 819–837 https://doi.org/10.1080/01902140600574967 PMID: 16684715

35. Cox RA, Burke AS, Traber DL, Herndon DN, Hawkins HK. Production of pro-inflammatory polypeptides by airway mucous glands and its potential significance. Pulm Pharmacol Ther 2007; 20: 172–177 https://doi.org/10.1016/j.pupt.2006.03.013 PMID: 16814583
36. Lange M, Nakano Y, Traber DL, Hamahata A, Traber LD, Enkhbaatar P. Time course of the inflammatory and oxidative stress response to pulmonary infection in mice. Exp Lung Res 2012; 38: 157–163. https://doi.org/10.3109/01902148.2012.663453 PMID: 22394289

37. Lange M, Szabo C, Traber DL, Horvath E, Hamahata A, Nakano Y, et al. Time profile of oxidative stress and neutrophil activation in ovine acute lung injury and sepsis. Shock 2012; 37: 468–472. https://doi.org/10.1097/SHK.0b013e31829408a9 PMID: 22266977

38. Rehberg S, Yamamoto Y, Sousse LE, Jonkam C, Zhu Y, Traber LD, et al. Antithrombin attenuates vascular leakage via inhibiting neutrophil activation in acute lung injury. Crit Care Med 2013; 41: e439–446. https://doi.org/10.1097/CCM.0b013e318298ad3a PMID: 24107637

39. Wang Q, Lian QQ, Li R, Ying BY, He Q, Chen F, et al. Lipoxin A(4) activates alveolar epithelial sodium channel, Na, K-ATPase, and increases alveolar fluid clearance. Am J Resp Cell Mol Biol 2013; 48: 610–618. https://doi.org/10.1165/rcmb.2012-0274OC PMID: 23470626

40. Fang XH, Abbott J, Cheng LD, Colby JK, Lee JW, Levy BD, et al. Human mesenchymal stem (stromal) cells promote the resolution of acute lung injury in part through lipoxin A4. J Immunol 2015; 195: 875–881. https://doi.org/10.4049/jimmunol.1500244 Epub 2015 Jun 26. PMID: 26115097

41. Orfanos SE, Kotanidou A, Glynos C, Athanasiou C, Tsikos S, Dimopoulos I, et al. Angiopoietin-2 is increased in severe sepsis: correlation with inflammatory mediators. Crit Care Med 2007; 35: 199–206 https://doi.org/10.1097/01.CCM.0000251640.77679.D7 PMID: 17110873

42. Van der Heijden M, van Nieuw Amerongen GP, Koolwijk P, van Hinsbergh VW, Groeneveld AB. Angiopoietin-2, permeability oedema, occurrence and severity of ALI/ARDS in septic and non-septic critically ill patients. Thorax 2008; 63: 903–909. https://doi.org/10.1136/thx.2007.087387 Epub 2008 Jun 17. PMID: 18559364

43. Parikh SM, Mammoto T, Schulz A, Yuan HT, Christiani D, Karumanchi SA, et al. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med 2006; 3: e46 https://doi.org/10.1371/journal.pmed.0030046 PMID: 16417407

44. Schreper S, Deuse T, Reichenspurner H, Fischbein MP, Robbins RC, Pelletier MP. Stem cell transplantation: The lung barrier. Transplant Proc 2007; 39: 573–576 https://doi.org/10.1016/j.transproceed.2006.12.019 PMID: 17362785

45. Fischer UM, Hartling MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cell Dev 2009; 18: 683–692. https://doi.org/10.1089/scd.2008.0253 PMID: 19099374

46. Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, Tessone A, et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium feasibility, cell migration, and body distribution. Circulation 2003; 108: 863–868 https://doi.org/10.1161/01.CIR.0000084828.50310.6A PMID: 12900340